Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUVOID vs DOXYCYCLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
Benign prostatic hyperplasia (BPH) - treatment of symptoms,Off-label: None established
Empiric treatment of acute bacterial exacerbations of COPD,Community-acquired pneumonia,Prostatitis caused by Chlamydia trachomatis,Treatment of Lyme disease,Treatment of Rocky Mountain spotted fever,Acne vulgaris (off-label),Malaria prophylaxis (off-label)
100 mg orally three times daily.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
Extensively metabolized in the liver primarily by CYP2D6 and CYP3A4, with possible minor contributions from other CYPs.
Doxycycline is partially metabolized in the liver via unspecified pathways; it is not significantly metabolized by CYP450 enzymes. Approximately 40% is excreted renally as active drug.
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Approximately 50–70% bound to plasma proteins, primarily albumin.
80–93% bound to plasma proteins, primarily albumin.
Vd approximately 0.6 L/kg, indicating distribution into total body water.
0.75–1.3 L/kg, indicating extensive tissue penetration; high concentrations in lung, liver, bone, and prostate.
Oral: 75–85% (may be decreased with food); subcutaneous: nearly 100%.
Oral: 90–100% (well absorbed); IV: 100%; topical: minimal systemic absorption (<10%).
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: avoid use.
For Cr Cl < 50 m L/min: no dosage adjustment required for most indications; for severe infections or prolonged use, consider monitoring renal function. In patients with Cr Cl < 10 m L/min, reduce dose or avoid if possible due to potential anti-anabolic effect.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 50 mg twice daily; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: use with caution; no specific dose reduction recommended. Child-Pugh C: avoid use due to lack of safety data.
Not recommended for use in pediatric patients.
For children >8 years and weighing ≤45 kg: 2.2 mg/kg every 12 hours on day 1, then 2.2 mg/kg once daily or 1.1 mg/kg every 12 hours. For children >45 kg: same as adult. For children <8 years: contraindicated due to risk of permanent tooth discoloration and enamel hypoplasia.
Initial dose 50 mg twice daily; titrate cautiously due to increased anticholinergic sensitivity.
No specific dose adjustment required; use standard adult dosing. Monitor renal function and consider potential increased risk of photosensitivity reactions. Avoid in elderly with impaired renal function if alternative agents available.
None.
There is no FDA black box warning for doxycycline.
Orthostatic hypotension (especially dose-related; syncope reported),Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Dizziness, somnolence, and fatigue may occur,Use caution with hepatic impairment,Avoid use with strong CYP3A4 inhibitors or inducers
Photosensitivity: avoid prolonged sun exposure,Esophageal injury: take with adequate fluids,Hepatotoxicity: caution in hepatic impairment,Intracranial hypertension: risk of pseudotumor cerebri,Delay in bone growth and tooth discoloration in children <8 years,C. difficile-associated diarrhea,Superinfection with resistant organisms
Hypersensitivity to DUVOID or any component,Moderate to severe hepatic impairment (Child-Pugh class B or C),Use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)
Hypersensitivity to tetracyclines,Children <8 years of age (except for anthrax or severe infections),Pregnancy (especially second and third trimesters)
Take on an empty stomach; food may decrease absorption. Avoid alcohol as it may increase cholinergic side effects.
Dairy products (milk, cheese, yogurt), calcium-fortified foods, antacids containing aluminum, calcium, magnesium, and iron supplements can chelate doxycycline, reducing absorption. Separate intake by at least 2 hours. Alcohol is not known to interact significantly. Avoid taking with high-iron foods like spinach or red meat within 2 hours.
DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus. No known specific trimester risks.
Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use associated with neural tube defects, cardiovascular malformations, and spontaneous abortion. Hepatic necrosis in pregnant women reported.
It is not known whether bethanechol is excreted in human milk. Caution should be exercised when administered to a nursing woman. M/P ratio is unknown.
Doxycycline is excreted into breast milk in low concentrations (M/P ratio ~0.2-0.6). Theoretical risk of dental staining and bone growth suppression in nursing infants. American Academy of Pediatrics considers compatible with breastfeeding due to low absorption, but alternative antibiotics preferred.
No formal pharmacokinetic studies in pregnancy. Due to increased plasma volume and renal clearance, dose adjustments may be necessary but specific recommendations are lacking. Use lowest effective dose and monitor clinical response.
Increased renal clearance and volume of distribution during pregnancy may reduce serum concentrations, but no dose adjustment recommended due to teratogenicity. Use only if absolutely necessary with caution.
DUVOID (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for cholinergic crisis (excessive salivation, sweating, bradycardia). Administer on an empty stomach to reduce GI upset. Avoid in patients with asthma, hyperthyroidism, peptic ulcer disease, or epilepsy. Atropine is the antidote for overdose.
Administer with a full glass of water to reduce esophageal irritation; avoid lying down for 30 minutes after dosing. Tetracyclines bind calcium, so avoid dairy, antacids, and iron within 2 hours of dosing. Use sun protection due to photosensitivity. In children under 8, pregnant, or breastfeeding, avoid due to tooth discoloration and bone growth inhibition. Monitor for superinfection, especially Clostridioides difficile. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Report any signs of excessive sweating, salivation, or bradycardia to your healthcare provider.,Avoid driving or operating machinery until you know how this drug affects you.,Do not stop taking this medication abruptly; consult your doctor for dose adjustments.,Keep a list of all medications you take and share with your healthcare provider.
Take exactly as prescribed; finish the full course even if you feel better.,Take with a full glass of water and remain upright for 30 minutes after.,Avoid dairy products, antacids, calcium supplements, iron, and magnesium within 2 hours of taking doxycycline.,Use sunscreen and protective clothing; avoid prolonged sun exposure as it can cause severe sunburn.,Do not take if pregnant, breastfeeding, or if you have a child under 8 years old.,Report any signs of severe diarrhea, skin rash, or difficulty swallowing to your doctor.,Store at room temperature away from moisture and heat; do not use outdated medication.
No interactions on record
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Ketobemidone, an opioid analgesic, may inhibit the cytochrome P450 enzyme CYP3A4, which is involved in the metabolism of doxycycline. This can lead to reduced clearance and increased plasma concentrations of doxycycline, potentially enhancing its antibiotic effects or increasing the risk of adverse effects such as photosensitivity, gastrointestinal disturbances, or hepatic toxicity."
"Clobazam, a benzodiazepine and CYP3A4 inducer, may increase the metabolism of doxycycline, a tetracycline antibiotic, reducing its plasma concentration and potentially compromising its antibacterial efficacy. This interaction could lead to subtherapeutic doxycycline levels, increasing the risk of treatment failure or microbial resistance. Conversely, doxycycline may inhibit CYP3A4, potentially elevating clobazam concentrations, though the clinical significance of this effect is less clear."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUVOID vs DOXYCYCLINE, answered by our medical review team.
DUVOID is a Cholinergic Agonist that works by Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.. DOXYCYCLINE is a Tetracycline Antibiotic that works by Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUVOID and DOXYCYCLINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUVOID is: 100 mg orally three times daily.. The standard adult dose of DOXYCYCLINE is: 100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUVOID and DOXYCYCLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUVOID is classified as Category C. DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be rul. DOXYCYCLINE is classified as Category D/X. Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use as. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.